Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This study found that men using 5-alpha-reductase inhibitors showed an increased risk for dementia shortly after starting treatment, which diminished over time, and a consistent association with depression, but no link to suicide.

This study developed a theoretical model that suggests finasteride may completely inhibit 5AR type 2, but not sufficiently suppress type 1, leading to only partial reduction of dihydrotestosterone at clinical doses.

This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.

This letter reports no new findings and discusses potential concerns regarding 5-alpha reductase inhibitors on lung function, suggesting a reason for discontinuation during the COVID-19 pandemic.

This article addresses the mechanisms of androgenic alopecia and seeks to clarify misconceptions, but it reports no new empirical findings and calls for further controlled studies.

This article reviews potential prevention and intervention strategies for prostate cancer, including 5alpha-reductase inhibition, but reports no new clinical findings.

This study found that a composition including Serenoa repens extract and anti-inflammatory agents effectively suppressed inflammation-related gene expression in a keratinocyte model, suggesting a potential dual strategy for treating androgenetic alopecia.

This article describes the growth and characteristics of saw palmetto and its fruit but reports no new research results.

This article discusses the familiarity of identifying male androgenetic alopecia but presents no new research findings.

This article discusses a novel multi-targeting approach to treating hair loss using standardized nutraceuticals but reports no new clinical results.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.

In laboratory tests, this study found that a novel natural composition targeting 5-alpha reductase and inflammatory pathways reduced disease-related markers in androgenetic alopecia and benign prostatic hyperplasia more effectively than finasteride.

This review highlights the potential of ginseng and its metabolites in preventing hair loss, detailing their hair growth-promoting effects observed in numerous preclinical studies, and emphasizing the underlying mechanisms involved.

This study found that Eclipta alba extracts exhibit 5α-reductase inhibitory activity, with the methanolic extract showing a higher concentration of β-sitosterol compared to petroleum ether extract, indicating potential for treating androgenic conditions like male pattern baldness.

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

This abstract reports funding sources for ongoing research and does not present any study results.

This review examines hormonal influences on acne development and available hormonal therapies but reports no new clinical results.

Isolation stress in rats reduces brain enzyme levels, affecting dopamine function.

This study examined finasteride, a 5-alpha-reductase inhibitor, for treating a Tourette’s syndrome patient unresponsive to traditional therapy, noting its limited side effects.

This study used computational methods to identify six molecules, with jamogenin being particularly promising, that effectively bind to and inhibit the enzyme linked to male pattern hair loss, suggesting these compounds could be explored further for hair growth potential.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This study observed that using only a 5 alpha-reductase inhibitor was ineffective for treating androgen-dependent hair loss in women, possibly due to differing copper levels influencing enzyme activity.

This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.

This study designed a novel model for 5a-reductase enzyme inhibitors using pharmacophore and 3D QSAR techniques, potentially allowing for improved prediction and development of drug therapies targeting benign prostatic hyperplasia.

This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.

Some types of hair loss can be reversed, others are permanent, and treatments vary by type.

This review discusses the potential benefits of the Restolin Hair Supplement for hair growth and reports no clinical results, with the authors noting that the claims are not supported by FDA approval or clinical trials.